Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial.

View through CrossRef
Background: Gastro-Esophageal reflux disease (GERD) is a very common problem in a gastrointestinal clinical setting. Still, the best treatment for it remains debatable as there are many new drugs that have evolved for its treatment in addition to dietary modification.Objective: To compare the clinical efficacy of Dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) for the resolution of symptoms of GERD.Material and Methods: This randomized controlled trial or intervention was conducted for comparing the clinical efficacy of Dexlansoprazolevs Esomeprazole for the symptomatic treatment of GERD.A total of 100 endoscopically diagnosed patients were selected and were randomly allocated to two groups each containing 50 patients. Group 'A' contained 50 patients who were given 60 mg Dexlansoprazole for 2 weeks and group 'B' also contained the same number of patients receiving the treatment with Esomeprazole 40 mg for the same duration.After informed consent, a validated tool FSSG (Frequency Scale for the Symptoms of GERD) was used to collect the responses of patients. The Chi-square test was used to compare the responses of two groups considering a P-value of <0.05 as significant.Results: Among domains of frequency scale for the symptoms of GERD, only dysphagia was significantly better in Dexlansoprazole group, P-valueof< 0.05 while rest of the symptoms were statistically same with a p-value of > 0.05.Conclusion: This study concluded that the symptomatic relief of GERD after 2 weeks of therapy with Esomeprazole and Dexlansoprazole was the same except for dysphagia.Keywords: Dexlansoprazole, Esomeprazole,Gastroesophageal reflux disease.
Title: Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial.
Description:
Background: Gastro-Esophageal reflux disease (GERD) is a very common problem in a gastrointestinal clinical setting.
Still, the best treatment for it remains debatable as there are many new drugs that have evolved for its treatment in addition to dietary modification.
Objective: To compare the clinical efficacy of Dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) for the resolution of symptoms of GERD.
Material and Methods: This randomized controlled trial or intervention was conducted for comparing the clinical efficacy of Dexlansoprazolevs Esomeprazole for the symptomatic treatment of GERD.
A total of 100 endoscopically diagnosed patients were selected and were randomly allocated to two groups each containing 50 patients.
Group 'A' contained 50 patients who were given 60 mg Dexlansoprazole for 2 weeks and group 'B' also contained the same number of patients receiving the treatment with Esomeprazole 40 mg for the same duration.
After informed consent, a validated tool FSSG (Frequency Scale for the Symptoms of GERD) was used to collect the responses of patients.
The Chi-square test was used to compare the responses of two groups considering a P-value of <0.
05 as significant.
Results: Among domains of frequency scale for the symptoms of GERD, only dysphagia was significantly better in Dexlansoprazole group, P-valueof< 0.
05 while rest of the symptoms were statistically same with a p-value of > 0.
05.
Conclusion: This study concluded that the symptomatic relief of GERD after 2 weeks of therapy with Esomeprazole and Dexlansoprazole was the same except for dysphagia.
Keywords: Dexlansoprazole, Esomeprazole,Gastroesophageal reflux disease.

Related Results

Impact of gastro-oesophageal reflux on microRNA expression, location and function
Impact of gastro-oesophageal reflux on microRNA expression, location and function
Abstract Background Ulceration of the oesophageal squamous mucosa (ulcerative oesophagitis) is a pathological manifestation of gastro-oesophageal...
Morning or evening dosage of omeprazole for gastro‐oesophageal reflux disease?
Morning or evening dosage of omeprazole for gastro‐oesophageal reflux disease?
SUMMARY Background and aims: When routinely checking patients receiving omeprazole treatment for gastro‐oesophageal reflux, we have been finding patients with surprisingly low noct...
Food-Stimulated Gastro-Oesophageal Reflux Demonstrated by Barium Examination
Food-Stimulated Gastro-Oesophageal Reflux Demonstrated by Barium Examination
A prospective investigation on gastro-oesophageal reflux in 97 consecutive patients has been carried out by means of a barium examination employing the conventional method and afte...
Pendekatan Diagnostik Refluks Laring Faring
Pendekatan Diagnostik Refluks Laring Faring
Abstract: Lifestyle and behavior changes can have bad impacts on our health. One of the diseases that can be caused by lifestyle changes is pharyngeal larynx reflux. Pharyngeal lar...
Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Background:The antiapoptotic and epithelial–mesenchymal transition activities of Twist have been implicated in the neoplastic transformation and the development of metastasis, resp...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top